About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Tennessee | 9,675 Studies Near You | Clareo Health

Clinical Trials LocationsTennessee

Clinical Trials in Tennessee

Discover 9,675 clinical trials near Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1881-1900 of 9,675 trials

COMPLETEDPhase 218 miles

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

NCT04856917

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

Vanda Pharmaceuticals123 participantsStarted May 2021

Hot Springs, Arkansas, United States • Fountain Valley, California, United States • Sherman Oaks, California, United States +12 more locations

TERMINATEDPhase 129 miles

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

NCT05200364

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Ovarian CancerOvarian CarcinomaOvary Cancer+2 more

Sutro Biopharma, Inc.58 participantsStarted Mar 2022

Tampa, Florida, United States • Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States +3 more locations

Find Trials by Condition in Tennessee

Breast Cancerin Tennessee Lung Cancerin Tennessee Prostate Cancerin Tennessee Colorectal Cancerin Tennessee Melanomain Tennessee Leukemiain Tennessee Lymphomain Tennessee Pancreatic Cancerin Tennessee Ovarian Cancerin Tennessee Brain Cancerin Tennessee

Data from ClinicalTrials.govTerms

RECRUITINGPhase 129 miles

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).

PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more

Relay Therapeutics, Inc.930 participantsStarted Dec 2021

Tucson, Arizona, United States • San Diego, California, United States • Denver, Colorado, United States +34 more locations

Active Not Recruiting71 miles

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

NCT03289780

The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.

Non-Small Cell Lung Cancer

Biodesix, Inc.5,006 participantsStarted Apr 2016

Huntsville, Alabama, United States • Tuscaloosa, Alabama, United States • Fayetteville, Arkansas, United States +39 more locations

Not Yet RecruitingNA154 miles

Weight Bearing After Pelvis and Acetabulum Fracture Fixation

NCT07189156

The goal of this study to determine if a randomized clinical trial of immediate versus delayed weight bearing after undergoing surgical fixation of a pelvis or acetabulum fracture is feasible. The main questions it aims to answer are: Are surgeons willing to allow inclusion of their patients into such a trial? Are patients willing to participate in such a trial? Will patients be compliant with assigned weight bearing status in such a trial? Can good patient follow-up be obtained in such a trial? Is participation in such a trial safe? Patients from 7 medical centers will be enrolled, and randomized to immediate weight bearing as tolerated (WBAT) versus delayed WBAT (for 6-12 weeks). Feasibility metrics revolving around enrollment, follow-up, and documentation will be monitored, as well as medical and surgical complications. This pilot study will help inform feasibility and design of a larger definitive multicenter randomized controlled trial (RCT) on this topic.

Pelvis FracturesAcetabulum Fractures

University of Mississippi Medical Center200 participantsStarted Oct 2025

Birmingham, Alabama, United States • Colton, California, United States • Indianapolis, Indiana, United States +4 more locations

Active Not RecruitingPhase 3154 miles

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

NCT01503632

This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia that has had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes.

Acute Lymphoblastic Leukemia

Children's Oncology Group570 participantsStarted Feb 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Downey, California, United States +99 more locations

COMPLETEDPhase 2154 miles

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

NCT05079035

It is hypothesized that a single Intra-articular Injection of TTAX03, 100mg in 2mL of saline, will have more benefit with respect to the proportion of responders 12 weeks post-injection than an equal volume of saline, based on the OMERACT-OARSI responder criteria.

Knee OsteoarthritisKnee Pain ChronicKnee Arthritis

BioTissue Holdings, Inc90 participantsStarted Dec 2021

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +7 more locations

COMPLETEDPhase 3156 miles

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

Type 2 Diabetes

Eli Lilly and Company1,698 participantsStarted Sep 2023

Phoenix, Arizona, United States • Canoga Park, California, United States • Escondido, California, United States +128 more locations

Active Not RecruitingPhase 4190 miles

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06112743

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

Cardiomyopathy, Hypertrophic

Bristol-Myers Squibb63 participantsStarted Jan 2024

West Hollywood, California, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +20 more locations

RECRUITINGPhase 1/2190 miles

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) regimen, and CCNE1-amplified solid tumors who progressed on standard of care treatment. The study will be conducted in 3 parts: Part A (INX-315 monotherapy dose escalation and combination therapy with fulvestrant), Part B (ovarian cancer INX-315 monotherapy dose expansion), and Part C (INX-315 combination therapy with abemaciclib \[a CDK4/6i\] and fulvestrant \[a SERD\] in advanced/metastatic breast cancer; dose escalation and expansion).

Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more

Incyclix Bio150 participantsStarted Mar 2023

Lake Mary, Florida, United States • Atlanta, Georgia, United States • Augusta, Georgia, United States +14 more locations

RECRUITINGPhase 2190 miles

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128

The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.

Irritable Bowel Syndrome

AbbVie95 participantsStarted Nov 2017

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • Corona, California, United States +43 more locations

Active Not RecruitingNA277 miles

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

NCT03681535

This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.

Diffuse Large B Cell Lymphoma

Duke University241 participantsStarted Feb 2019

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Weymouth, Massachusetts, United States +9 more locations

RECRUITING362 miles

Clinical Procedures to Support Research in ALS

NCT03489278

The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.

Amyotrophic Lateral SclerosisALS-Frontotemporal DementiaPrimary Lateral Sclerosis+1 more

University of Miami1,200 participantsStarted Feb 2018

Irvine, California, United States • Palo Alto, California, United States • San Francisco, California, United States +8 more locations

RECRUITINGPhase 3432 miles

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289

The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.

Ulcerative ColitisCrohn's Disease

Takeda70 participantsStarted Jan 2025

Garden Grove, California, United States • Loma Linda, California, United States • Orange, California, United States +54 more locations

Active Not RecruitingPhase 2434 miles

4D-150 in Patients With Diabetic Macular Edema

NCT05930561

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Diabetic Macular EdemaDiabetic Retinopathy

4D Molecular Therapeutics72 participantsStarted Aug 2023

Hagerstown, Maryland, United States • Eugene, Oregon, United States • Erie, Pennsylvania, United States +3 more locations

Active Not RecruitingEARLY Phase 1437 miles

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707

The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. Fluoxetine, a drug approved by the FDA to treat problems like depression and anxiety, can cause changes to structures in cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain.

Primary Brain TumorBrain Tumor, Recurrent

Duke University10 participantsStarted Aug 2023

San Diego, California, United States • Stanford, California, United States • New York, New York, United States +1 more locations

RECRUITING474 miles

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

NCT06279572

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Acute Myeloid Leukemia

Mayo Clinic80 participantsStarted Apr 2021

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETED480 miles

EchoTip AcuCore Post-Market Clinical Study

NCT06358001

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

AdenocarcinomaNeuroendocrine TumorsHepatocellular Carcinoma+5 more

Cook Research Incorporated183 participantsStarted Aug 2024

Orange, California, United States • Denver, Colorado, United States • Gainesville, Florida, United States +5 more locations

Active Not RecruitingPhase 2604 miles

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

NCT06033833

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.

Sanofi335 participantsStarted Sep 2023

Stockton, California, United States • Boynton Beach, Florida, United States • Miami, Florida, United States +65 more locations

Active Not RecruitingPhase 1/2651 miles

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.

Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides+5 more

City of Hope Medical Center38 participantsStarted Mar 2017

Duarte, California, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States +1 more locations

PreviousPage 95 of 484Next

Diabetes

in Tennessee

Heart Diseasein Tennessee